The final results are in, and they’re incredibly positive. The Kailo Pain Patch works. On January 30, 2022 Pain Relief Technologies LLC and Kailo Pain Patch® announced the IRB-Approved PREVENT study’s final results. The trial produced positive results in patients with mild, moderate, and severe pain conditions, with resounding support from nearly all participants.
No time to read the full trial results? We have you covered with a brief outline of the trial and its outcome. The study was administered by Clarity Science LLC, a respected international scientific research company, and led by Dr. Jeffrey Gudin, the principal investigator.
The clinical trial results represent the outcomes from the PREVENT study. PREVENT is an IRB-approved, minimal-risk, observational trial.
The trial evaluated a group of 128 patients with mild, moderate, and severe pain and neuropathic, musculoskeletal, and arthritic conditions. Their changes in pain severity, medication usage, pain interference, and side effects were closely monitored and evaluated.